<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286311</url>
  </required_header>
  <id_info>
    <org_study_id>Reducing CV Risk</org_study_id>
    <secondary_id>K08HS015647</secondary_id>
    <nct_id>NCT01286311</nct_id>
  </id_info>
  <brief_title>Tailored Communication to Reduce Cardiovascular Risk</brief_title>
  <official_title>Tailored Communication to Reduce Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the trial is to test the feasibility and efficacy of a cardiovascular
      disease quality improvement system that couples EMR-based patient identification with
      individually tailored patient messages. The study will test the hypothesis that that a
      tailored patient-directed approach to cardiovascular risk reduction integrated into patients'
      primary care delivery site will improve control of elevated low-density lipoprotein
      cholesterol and other card iac risk factors more than routine care alone for patients at
      intermediate or high risk for cardiovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction</measure>
    <time_frame>9 months</time_frame>
    <description>Significant LDL cholesterol reduction at 9 months Definition: Percentage of patients with LDL-C repeated and which is at least 30 mg/dl lower than baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Clinical Encounters</measure>
    <time_frame>9 months</time_frame>
    <description>This will measure the difference in frequency of clinical encounters in the electronic medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Prescriptions for Dyslipidemia</measure>
    <time_frame>9 months</time_frame>
    <description>This will look at whether lipid lowering medications (LLM) were prescribed for dyslipidemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Uncontrolled Hypertension Who Had an Increase in the Number of Antihypertensive Medication Drug Classes Prescribed</measure>
    <time_frame>9 months</time_frame>
    <description>This will measure the percentage of participants who had uncontrolled hypertension at baseline who had an increase in the number of antihypertensive medication drug classes prescribed within 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of an Aspirin Prescription</measure>
    <time_frame>9 months</time_frame>
    <description>This will measure the presence of an aspirin prescriptions on the medication list in the electronic medical record.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">464</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Dyslipidemia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Direct-to-patient tailored cardiovascular risk message system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Direct-to-patient tailored cardiovascular risk message system</intervention_name>
    <description>Patient informational mailings</description>
    <arm_group_label>Direct-to-patient tailored cardiovascular risk message system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 to 79 years

          -  medication list does not include an active lipid lowering medication

          -  the patient does not have a diagnosis in the past medical history, active problem list
             or past visit encounter of coronary heart disease, heart failure, stroke, diabetes
             mellitus, or peripheral arterial disease

          -  the patient has an enrolled study physician recorded as his/her primary care physician

          -  the patient has an LDL cholesterol that meets one or more of the criteria listed
             below.

        LDL cholesterol &gt;= 130 mg/dl and estimated Framingham Risk Score 10-20% LDL cholesterol &gt;=
        100 mg/dl and estimated Framingham Risk Score &gt;20% LDL cholesterol &gt;= 160 mg/dl and
        estimated Framingham Risk Score 5% to &lt;10%.

        Exclusion Criteria:

          -  Age &lt;40 or &gt;79 years

          -  medication list includes an active lipid lowering medication

          -  the patient hase a diagnosis in the past medical history, active problem list or past
             visit encounter of coronary heart disease, heart failure, stroke, diabetes mellitus,
             or peripheral arterial disease

          -  the patient does not have an enrolled study physician recorded as his/her primary care
             physician

          -  the patient does not have an LDL cholesterol that meets one or more of the criteria
             listed below.

        LDL cholesterol &gt;= 130 mg/dl and estimated Framingham Risk Score 10-20% LDL cholesterol &gt;=
        100 mg/dl and estimated Framingham Risk Score &gt;20% LDL cholesterol &gt;= 160 mg/dl and
        estimated Framingham Risk Score 5% to &lt;10%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Persell, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Division of General Internal Medicine, Feinberg School of Medicine and Institute for Healthcare Studies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation General Internal Medicine Ambulatory Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <results_first_submitted>May 13, 2013</results_first_submitted>
  <results_first_submitted_qc>January 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2015</results_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Stephen Persell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Health Education</keyword>
  <keyword>Health Knowledge, Attitudes, Practice</keyword>
  <keyword>Hypolipidemic Agents/therapeutic use</keyword>
  <keyword>Patient Education as Topic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Physicians were recruited at their clinic offices in January 2011. They provided written informed consent to be randomized and to have study staff mail risk messages directly to patients on their behalf if they were randomized to the intervention. Patients were included with a waiver of consent.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
          <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Eligible patients cared for by physicians randomized to the control group will receive usual care. After 9 months, control group physicians were provided with lists of their eligible patients and their risk scores.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="232">218 patients (of the 14 physician randomized to the intervention) started the study.</participants>
                <participants group_id="P2" count="232">217 patients (of the 15 physician randomized to the intervention) started the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218">204 patients (of the 14 physician randomized to the intervention) completed the study.</participants>
                <participants group_id="P2" count="232">217 patients (of the 15 physician randomized to the intervention) completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician did not want outreach sent</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>218 patients (of the 14 physician randomized to the intervention) and 217 patients (of the 15 physician randomized to the intervention) participated in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
          <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="232"/>
            <count group_id="B2" value="232"/>
            <count group_id="B3" value="464"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Physicians were not enrolled according to age criteria, and are therefore not included above.</description>
          <units>patient participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.4"/>
                    <measurement group_id="B2" value="60.1" spread="9.2"/>
                    <measurement group_id="B3" value="60.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Physicians were not enrolled according to gender criteria, and are therefore not included above.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction</title>
        <description>Significant LDL cholesterol reduction at 9 months Definition: Percentage of patients with LDL-C repeated and which is at least 30 mg/dl lower than baseline</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
            <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Eligible patients cared for by physicians randomized to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction</title>
          <description>Significant LDL cholesterol reduction at 9 months Definition: Percentage of patients with LDL-C repeated and which is at least 30 mg/dl lower than baseline</description>
          <units>% of patients with major LDL reduction</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Generalized Logistic Regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Clinical Encounters</title>
        <description>This will measure the difference in frequency of clinical encounters in the electronic medical record.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
            <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Eligible patients cared for by physicians randomized to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Clinical Encounters</title>
          <description>This will measure the difference in frequency of clinical encounters in the electronic medical record.</description>
          <units>% of patients with any office visit</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="56.7" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Generalized Logistic Regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Prescriptions for Dyslipidemia</title>
        <description>This will look at whether lipid lowering medications (LLM) were prescribed for dyslipidemia.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
            <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Eligible patients cared for by physicians randomized to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Prescriptions for Dyslipidemia</title>
          <description>This will look at whether lipid lowering medications (LLM) were prescribed for dyslipidemia.</description>
          <units>% of patients with New Rx for LLM</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Generalized Logistic Regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Uncontrolled Hypertension Who Had an Increase in the Number of Antihypertensive Medication Drug Classes Prescribed</title>
        <description>This will measure the percentage of participants who had uncontrolled hypertension at baseline who had an increase in the number of antihypertensive medication drug classes prescribed within 9 months.</description>
        <time_frame>9 months</time_frame>
        <population>Among patients with uncontrolled hypertension, 76 of the 218 in the intervention arm and 85 of 217 in the control arm were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
            <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Eligible patients cared for by physicians randomized to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Uncontrolled Hypertension Who Had an Increase in the Number of Antihypertensive Medication Drug Classes Prescribed</title>
          <description>This will measure the percentage of participants who had uncontrolled hypertension at baseline who had an increase in the number of antihypertensive medication drug classes prescribed within 9 months.</description>
          <population>Among patients with uncontrolled hypertension, 76 of the 218 in the intervention arm and 85 of 217 in the control arm were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Generalized Logistic Regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of an Aspirin Prescription</title>
        <description>This will measure the presence of an aspirin prescriptions on the medication list in the electronic medical record.</description>
        <time_frame>9 months</time_frame>
        <population>38 patients in the intervention arm and 50 patients in the control arm had aspirin listed in their medication list in the electronic medical record as the start of the study therefore they were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
            <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Eligible patients cared for by physicians randomized to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of an Aspirin Prescription</title>
          <description>This will measure the presence of an aspirin prescriptions on the medication list in the electronic medical record.</description>
          <population>38 patients in the intervention arm and 50 patients in the control arm had aspirin listed in their medication list in the electronic medical record as the start of the study therefore they were excluded from this analysis.</population>
          <units>% patients w/aspirin now on med list</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Generalized Logistic Regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/addressed. As a result, no participants were at risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Direct-to-patient Tailored Cardiovascular Risk Message System</title>
          <description>Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Eligible patients cared for by physicians randomized to the control group will receive usual care.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen D. Persell, MD MPH</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-6464</phone>
      <email>spersell@nmff.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

